FLT3, ASXL1, or TP53 mutations in AML Not otherwise specified (NOS) were detected in three patients of the CA4+3 group, while FLT3high mutations without CBFB‐MYH11 or NPM1 in four patients and TP53 mutations in one patient with AML NOS were identified in the CA4+5 group (Figure 1). This evidence concerns the gene FLT3 and acute myeloid leukemia.